<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226096</url>
  </required_header>
  <id_info>
    <org_study_id>NDA1INTERACT</org_study_id>
    <nct_id>NCT00226096</nct_id>
  </id_info>
  <brief_title>Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage</brief_title>
  <official_title>A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether lowering high blood pressure levels after
      the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce
      the chances of a person dying or surviving with a long term disability. The study will be
      undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracerebral haemorrhage (ICH) is one of the most serious subtypes of stroke, affecting
      approximately 2-3 million people worldwide each year. About one third of people with ICH die
      early after onset and the majority of survivors are left with major long-term disability.
      Administration of activated recombinant human Factor VII has been shown to limit haematoma
      expansion in randomised controlled clinical trials; however, future clinical use of this
      agent may be limited by a short therapeutic time window, contraindication in patients at risk
      of thromboembolism and high cost. Currently, no acute medical therapies have been shown to
      alter outcome in ICH and the role of surgery remains uncertain.

      Blood pressure (BP) levels are strongly and positively associated with the incidence of first
      and recurrent stroke and there is definite evidence that BP lowering reduces stroke risk.
      Although BP levels are commonly elevated after stroke onset, particularly in ICH, the effects
      of BP lowering treatment in the acute phase of stroke remain unknown.

      The study aims to establish the effectiveness of a management policy of early intensive BP
      lowering on death &amp; disability in patients with primary ICH compared to current
      guideline-based management of high BP in the clinical setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combination death and dependency, according to a 3-6 scores on the modified Rankin Score.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause and cause-specific early neurological deterioration during the first 72 hours; haematoma expansion &amp; cerebral oedema at 24 &amp; 72 hours; ; functional disability; cognitive function; quality of life; mortality at 1 and 3 months</measure>
    <time_frame>24 and 72 hours, 1 and 3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">404</enrollment>
  <condition>CVA (Cerebrovascular Accident)</condition>
  <condition>Cerebral Hemorrhage</condition>
  <condition>Intracranial Hemorrhages</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol Hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol tartrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydralazine Hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerol Trinitrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urapidil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalaprilat</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroprusside</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or above

          -  Acute stroke due to spontaneous ICH confirmed by clinical history &amp; CT scan

          -  At least 2 systolic BP measurements of &gt;/=150mmHg and &lt;/=220mmHg, recorded 2 or more
             minutes apart

          -  Able to commence randomly assigned BP lowering regimen within 6 hours of stroke onset

          -  Able to be actively treated and admitted to a monitored facility e.g. HDU/ICU/acute
             stroke unit

        Exclusion Criteria:

          -  Known definite contraindication to an intensive BP lowering regimen

          -  Known definite indication for intensive BP lowering regimen as (or more) intensive
             than the active treatment arm

          -  Definite evidence that the ICH is secondary to a structural abnormality in the brain

          -  Previous ischaemic stroke within 30 days

          -  A very high likelihood that the patient will die within the next 24 hours on the basis
             of clinical and/or radiological criteria

          -  Known advanced dementia or significant pre-stroke disability

          -  Concomitant medical illness that would interfere with outcome assessments and follow
             up

          -  Already booked for surgical evacuation of haematoma

          -  Previous participation in this trial or current participation in another
             investigational drug trial

          -  A high likelihood that the patient will not adhere to the study treatment and follow
             up regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Anderson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Neal, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2138</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Coordinating Centre: Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitals in China, c/o The George Institute China</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Coordinating Centre: Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Second Medical University</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://www.thegeorgeinstitute.org</url>
    <description>For further information please see The George Institute for International health's website.</description>
  </link>
  <results_reference>
    <citation>Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008 May;7(5):391-9. doi: 10.1016/S1474-4422(08)70069-3. Epub 2008 Apr 7.</citation>
    <PMID>18396107</PMID>
  </results_reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>June 25, 2008</last_update_submitted>
  <last_update_submitted_qc>June 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2008</last_update_posted>
  <keyword>Clinical Trial</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>CVA (Cerebrovascular Accident)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Urapidil</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Esmolol</mesh_term>
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

